Hong Kong stock market anomaly | Stone Pharmaceutical Group (01093.HK) rose more than 3%. The Phase II clinical trial of SYS 6026 injection for the treatment of HPV16 or 18-related HSIL has officially started in China.
According to the Securities Times App, Sino Pharmaceutical Group (01093.HK) rose more than 3%, as of the time of publication, it has risen by 3.11% to HK $8.67, with a turnover of HK $152 million.
Latest
3 m ago
